Onset of Motor Complications and Medication Dose in Newly Diagnosed and Treated Parkinson’s Disease
Parkinson's Disease · 2026-01 · 2026 (1)
DOI: 10.1155/padi/8827381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Parkinson's Disease, online erschienen am 31.07.2026. Verfasst von Yasushi Osaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kochi Medical School Hospital, Kohasu Oko-cho, Nankoku-shi 785-8505, Kochi, Japan. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Parkinson’s disease (PD) patients under medical treatment experience motor complications (MCs), namely, ON/OFF fluctuations (ON/OFF) and dyskinesias.
Methods
We assessed 120 newly diagnosed PD patients after the initiation of medical treatment who were followed up for at least 24 months. We reviewed the latency of ON/OFF or dyskinesias by months and calculated the levodopa dose (LD), levodopa dose divided by daily intake (LDdiv), and levodopa equivalent dose (LED). We estimated cumulative incidence and median latency by Kaplan–Meier survival analysis. We classified patients with MCs into four groups and patients with ON/OFF or dyskinesias into three groups, according to latency.
Results
Seventy‐six patients experienced MCs with a median latency of 28 months. Fifty‐seven patients experienced ON/OFF and 19 experienced dyskinesias with a median latency of 28 and 50 months, respectively. The medication dose at which each patient experienced ON/OFF or dyskinesias varied widely. The median LD, LDdiv, and LED was 300 (237.5–350), 100 (79–111), and 300 (250–450) mg at the onset of MCs; 300 (200–300), 100 (83–125), and 300 (249–400) mg at the onset of ON/OFF; and 400 (375–500), 125 (105–133), and 600 (466–722.75) mg at the onset of dyskinesias, respectively. Consistently, the shortest latency group had the lowest medication dose, while the longest latency group had the highest. Five patients experienced dyskinesias before ON/OFF, with similar medication doses at the onset of ON/OFF and dyskinesias. Some patients experienced ON/OFF but have not yet developed dyskinesias under a comparable medication dose as patients who experienced dyskinesias; the latter had a significantly younger age at onset.
Conclusions
The pathophysiological backgrounds and changes causing ON/OFF or dyskinesias are not the same for all patients. The presence of ON/OFF and higher medication doses does not always cause dyskinesias. A younger age at onset may be associated with the occurrence of dyskinesias.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Kochi Medical School Hospital, Kohasu Oko-cho, Nankoku-shi 785-8505, Kochi, Japan.
ORCID-Profile: Yasushi Osaki, Yukari Morita
Zitieren
APA
Osaki, Y., Morita, Y., Ohtsuru, S., Shogase, T., Yoshimoto, D., Ikeda, T., Kabeya, S., Hashimoto, Y., & Matsushita, T. (2026). Onset of Motor Complications and Medication Dose in Newly Diagnosed and Treated Parkinson’s Disease. Parkinson's Disease, 2026(1). https://doi.org/10.1155/padi/8827381
Vancouver
Osaki Y, Morita Y, Ohtsuru S, Shogase T, Yoshimoto D, Ikeda T, et al. Onset of Motor Complications and Medication Dose in Newly Diagnosed and Treated Parkinson’s Disease. Parkinson's Disease. 2026;2026(1). doi:10.1155/padi/8827381
BibTeX
@article{Osaki2026,
author = {Osaki, Yasushi and Morita, Yukari and Ohtsuru, Sho and Shogase, Tomohiro and Yoshimoto, Daiji and Ikeda, Tatsuya and Kabeya, Sayomi and Hashimoto, Yu and Matsushita, Takuya},
title = {Onset of Motor Complications and Medication Dose in Newly Diagnosed and Treated Parkinson’s Disease},
journal = {Parkinson's Disease},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/padi/8827381}
}
EUVIMED